Literature DB >> 16019586

Glucocorticoid receptor function in vitro in patients with major depression.

Carmine M Pariante1.   

Abstract

Clinical studies have demonstrated an impairment of glucocorticoid receptor (GR)-mediated negative feedback on the hypothalamic--pituitary--adrenal (HPA) axis in patients with major depression (GR resistance), and its resolution by antidepressant treatment. Interestingly, a number of studies have also demonstrated that GR function is reduced in vitro, in peripheral tissues of depressed patients, as shown by a decreased sensitivity to the effects of glucocorticoids on immune and metabolic functions. This paper reviews the in vitro studies that have examined GR function in patients with major depression, and the possible molecular mechanisms involved in GR resistance. Since several studies have demonstrated similar regulation of GR in the brain and in peripheral tissues in humans, and given limited access to brain GR in clinical populations, this review claims that in vitro studies are of particular relevance to understand the molecular mechanisms underlying GR abnormalities in patients with major depression and its regulation by antidepressant treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 16019586     DOI: 10.1080/10253890500069650

Source DB:  PubMed          Journal:  Stress        ISSN: 1025-3890            Impact factor:   3.493


  40 in total

1.  Clomipramine in vitro reduces glucocorticoid receptor function in healthy subjects but not in patients with major depression.

Authors:  Livia A Carvalho; Mario F Juruena; Andrew S Papadopoulos; Lucia Poon; Rob Kerwin; Anthony J Cleare; Carmine M Pariante
Journal:  Neuropsychopharmacology       Date:  2008-03-26       Impact factor: 7.853

Review 2.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

3.  Estradiol stimulates an anti-translocation expression pattern of glucocorticoid co-regulators in a hippocampal cell model.

Authors:  Sanjana A Malviya; Sean D Kelly; Megan M Greenlee; Douglas C Eaton; Billie Jeanne Duke; Chase H Bourke; Gretchen N Neigh
Journal:  Physiol Behav       Date:  2013-03-26

4.  Hormones, stress, and cognition: The effects of glucocorticoids and oxytocin on memory.

Authors:  Michelle M Wirth
Journal:  Adapt Human Behav Physiol       Date:  2015-06-01

Review 5.  Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression.

Authors:  Thaddeus W W Pace; Fang Hu; Andrew H Miller
Journal:  Brain Behav Immun       Date:  2006-10-27       Impact factor: 7.217

Review 6.  Risk factors for development of depression and psychosis. Glucocorticoid receptors and pituitary implications for treatment with antidepressant and glucocorticoids.

Authors:  Carmine M Pariante
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

Review 7.  Glucocorticoid dysregulations and their clinical correlates. From receptors to therapeutics.

Authors:  Andrea H Marques; Marni N Silverman; Esther M Sternberg
Journal:  Ann N Y Acad Sci       Date:  2009-10       Impact factor: 5.691

8.  Origin of ultradian pulsatility in the hypothalamic-pituitary-adrenal axis.

Authors:  Jamie J Walker; John R Terry; Stafford L Lightman
Journal:  Proc Biol Sci       Date:  2010-02-03       Impact factor: 5.349

9.  Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding.

Authors:  Francesca Spiga; David M Knight; Susanne K Droste; Becky Conway-Campbell; Yvonne Kershaw; Cliona P MacSweeney; Fiona J Thomson; Mark Craighead; Bernard W M M Peeters; Stafford L Lightman
Journal:  J Psychopharmacol       Date:  2010-01-21       Impact factor: 4.153

10.  Hypothalamic-pituitary-adrenal axis abnormalities in response to deletion of 11beta-HSD1 is strain-dependent.

Authors:  R N Carter; J M Paterson; U Tworowska; D J Stenvers; J J Mullins; J R Seckl; M C Holmes
Journal:  J Neuroendocrinol       Date:  2009-07-07       Impact factor: 3.627

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.